Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.89 |
| ▸ | BRD2 | P25440 | 1/20 | 0.71 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.71 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20887706 | 1.00 | BRD4 (0.89) | BRD4BRD2BRD3BRDTPTGS1 | |
| SCHEMBL29595883 | 1.00 | BRD4 (0.89) | BRD4BRD2BRD3BRDTPTGS1 | |
| SCHEMBL22408442 | 0.94 | BRD4 (1.00) | BRD4BRD2BRD3BRDTPTGS1 | |
| SCHEMBL20876241 | 0.94 | BRD4 (1.00) | BRD4BRD2BRD3BRDTPTGS1 | |
| SCHEMBL29595739 | 0.94 | BRD4 (1.00) | BRD4BRD2BRD3BRDTPTGS1 | |
| SCHEMBL20887726 | 0.91 | BRD4 (0.85) | BRD4BRD2BRD3BRDTF10 | |
| SCHEMBL20887696 | 0.90 | BRD4 (0.83) | BRD4BRD2BRD3BRDTPTGS1 | |
| SCHEMBL29595698 | 0.90 | BRD4 (0.83) | BRD4BRD2BRD3BRDTPTGS1 | |
| SCHEMBL22430964 | 0.90 | BRD4 (0.83) | BRD4BRD2BRD3BRDTPTGS1 | |
| SCHEMBL29595721 | 0.90 | BRD4 (0.83) | BRD4BRD2BRD3BRDTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| US-20200291009-A1 | 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200291009-A1 | 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| EP-3692036-A1 | 2,3-DIHYDROBENZOFURANS AS BOROMODOMAIN INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019068782-A1 | 2,3-DIHYDROBENZOFURANS AS BOROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019068782-A1 | 2,3-DIHYDROBENZOFURANS AS BOROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291009-A1 | 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD3 | BRD4 1/4885BRD2 5/4885BRD3 3/4885 |
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885BRD2 4/4885BRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.